Understanding Ketamine Nonresponse in Bipolar Depression
Ketamine has gained attention as a rapid-acting antidepressant, especially for people living with treatment-resistant bipolar depression (TRBD). While many patients experience significant improvements, recent research shows that not everyone responds to this therapy. This raises an important question: why does ketamine work well for some individuals but not for others?
A new study followed 35 patients with TRBD who received either intravenous ketamine infusions or oral doses over a four-week period. The results revealed that about 40 percent of participants did not show meaningful improvement in their depressive symptoms. This highlights the reality that ketamine, while promising, is not a universal solution.
Key Factors Linked to Nonresponse
The study identified a few features that were more common in patients who did not benefit from ketamine treatment:
- Psychiatric comorbidities: Nonresponders tended to have a higher number of coexisting mental health conditions compared to responders.
- Benzodiazepine use: Those with a history of benzodiazepine use were more likely to experience limited benefits from ketamine.
- No link with suicidality: Interestingly, baseline suicidality did not seem to predict whether a patient would respond or not.
These findings suggest that the overall complexity of a person’s psychiatric profile may influence the effectiveness of ketamine in bipolar depression.
What Nonresponse Means for Patients
For individuals living with bipolar depression, nonresponse can be disheartening. Patients may enter ketamine treatment with high expectations, especially given the excitement around its rapid effects. When symptoms remain unchanged, this can feel like another setback in a long journey through different medications and therapies.
Clinicians stress that nonresponse does not mean failure. Instead, it highlights the importance of exploring alternative options. Patients who do not improve with ketamine may still benefit from other evidence-based interventional treatments or combinations of therapies tailored to their unique needs.
Comparing Ketamine With Other Interventional Approaches
While ketamine continues to show promise, other interventional psychiatry options can provide alternatives for patients who do not respond:
- Esketamine nasal spray (Spravato): Approved for treatment-resistant depression, this formulation is delivered differently and may work for some patients who did not benefit from intravenous ketamine.
- Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation method with growing evidence in bipolar depression.
- Electroconvulsive Therapy (ECT): Though sometimes stigmatized, ECT remains one of the most effective treatments for severe, resistant mood disorders.
- Emerging psychedelic therapies: Psilocybin and MDMA-assisted therapies are under investigation and may provide future options for those with limited response to current treatments.
This broader landscape shows that while ketamine is an important tool, it is part of a larger set of evolving strategies in interventional psychiatry.
Moving Toward Personalization
The future of psychiatry is likely to focus on tailoring treatments to the individual. Just as not all patients with bipolar depression respond to the same medications, not all will benefit equally from ketamine. Combining clinical insights with precision tools such as neuroimaging, biomarkers, and digital monitoring could help match the right patient with the right therapy.
Personalized medicine may also help identify patients at higher risk of nonresponse before treatment begins, saving time, resources, and emotional strain. The ultimate goal is to create a system where patients are guided toward the most effective interventions as early as possible.
Conclusion
Ketamine has changed the way clinicians approach treatment-resistant bipolar depression, but ketamine nonresponse in bipolar depression reminds us that there is no single solution for everyone. By studying why some patients do not respond, researchers are paving the way for more individualized and effective care. The journey toward precision psychiatry is still unfolding, and each study brings us closer to a future where treatments are matched to the unique needs of every patient.
References
- Walaszek M, Cubała WJ, Kachlik Z, Pastuszak M, Pastuszak K, Kwaśny A. Non-response to short-term ketamine use for treatment-resistant depression. Pharmacol Rep. 2025;77(4):1126-1133. https://pubmed.ncbi.nlm.nih.gov/40305000/
- McIntyre RS, Alda M, Baldessarini RJ, et al. The Clinical Characterization of the Adult Patient With Bipolar Disorder Aimed at Personalization of Management. World Psychiatry. 2022;21(3):364–387. https://pubmed.ncbi.nlm.nih.gov/35929471/